Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 25, 2025 04:00 ET | Source: Alvotech

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of...
June 25, 2025 04:00 ET | Source: Alvotech

Jákvæð niðurstaða úr klínískri rannsókn fyrir fyrirhugaða hliðstæðu Alvotech við líftæknilyfið Xolair

Alvotech (NASDAQ: ALVO) og samstarfsaðilar félagsins, Kashiv Biosciences og Advanz Pharma, kynntu í dag að jákvæð niðurstaða hefði náðst í klínískri rannsókn sem bar saman virkni AVT23, fyrirhugaðrar...
June 25, 2025 04:00 ET | Source: Alvotech

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines...
June 23, 2025 04:00 ET | Source: Alvotech

Lyfjastofnun Evrópu mælir með því að veita markaðsleyfi fyrir AVT06, fyrirhugaða hliðstæðu Alvotech við augnlyfið Eylea

Mannalyfjanefnd (CHMP) Lyfjastofnunar Evrópu (EMA) hefur mælt með því að heimila markaðssetningu AVT06, sem er fyrirhuguð hliðstæða augnlyfsins Eylea (aflibercept), þróuð af Alvotech. Framkvæmdastjórn...
June 23, 2025 04:00 ET | Source: Alvotech

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and...
June 23, 2025 04:00 ET | Source: Alvotech

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
June 11, 2025 16:20 ET | Source: Alvotech

Öll bréf afhent kaupendum í hlutafjárútboði Alvotech

Alvotech (NASDAQ: ALVO, ALVO-SDB) tilkynnti í dag að fyrirtækið afhent bréf til þátttakenda í lokuðu hlutafjárútboði sem fram fór þann 4. júní sl. Um 40 stofnanafjárfestar tóku þátt í útboðinu. Um 60%...
June 11, 2025 16:20 ET | Source: Alvotech

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the...
June 11, 2025 16:18 ET | Source: Alvotech

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the...
June 06, 2025 08:30 ET | Source: Alvotech

Alvotech tekur þátt í árlegri heilbrigðisráðstefnu Goldman Sachs fjárfestingabankans í Miami

Alvotech (NASDAQ: ALVO) tekur þátt í árlegri heilbrigðisráðstefnu Goldman Sachs fjárfestingabankans sem haldin verður í Miami dagana 9.-11. júní nk. Fulltrúar félagsins funda með einstökum fjárfestum...